The stability test chamber and walk-in constant temperature and humidity chamber of Lanbeishi drug are widely used in Nanjing Huawei

Nanjing Huawei Pharmaceutical Technology Group Co., LtdEstablished in 2000, Huawei Pharmaceuticals is a high-tech enterprise specializing in drug discovery, research, and technical services. It is a national high-tech enterprise (2012/2015), Jiangsu Province enterprise (2014), Jiangsu Province private enterprise (2013), Jiangsu Province private technology enterprise (2012), Jiangsu Province enterprise graduate workstation (2015), Jiangsu Province enterprise technology center (2016), Jiangsu Province Targeted Anti tumor Drug Engineering Technology Research Center (2016), and ISO9001 quality management system certified enterprise (2014).

Huawei Pharmaceuticals currently has 5 wholly-owned subsidiaries and 1 joint venture: Nanjing Weinuode Pharmaceutical Technology Co., Ltd. (Weinuode Pharmaceutical), Jiangsu Lihua Biotechnology Co., Ltd. (Lihua Biotechnology), Nanjing Simosibo Detection Technology Co., Ltd. (Simosibo), Nanjing Simoo Pharmaceutical Technology Co., Ltd. (Simoo), and Nanjing Huanglong Biotechnology Co., Ltd. (Huanglong Biotechnology). Winode Pharmaceuticals is mainly engaged in the production and sales of customized synthesis, CMO, API, and related intermediates; Lihua Biotechnology is mainly engaged in clinical CRO and import registration services for drugs/devices; Simersbo has established a biological sample analysis and testing business for BE/PK in accordance with GLP standards; Ximuou mainly engages in SMO expatriate CRC services; Huanglong Biotechnology is mainly engaged in the research and development of biopolymer peptide drugs; The joint venture company Kangyuan Huawei Pharmaceutical Co., Ltd. is mainly engaged in the business of drug marketing authorization holders (MAHs).

Huawei Pharmaceuticals currently owns two office research and development buildings in Xianlin University City, Nanjing, China, with an investment of over 300 million RMB and a total area of approximately 30000 square meters. The buildings are equipped with advanced new drug research instruments and equipment, as well as a new drug research and development management system and functional departments. The company's R&D management team, with multiple PhDs at its core, focuses on the research of cutting-edge technologies such as chiral synthesis, controlled release technology, targeted drug delivery systems, and screening of new molecular drugs. It has achieved over 100 Chinese and PCT technology inventions; The company currently has a professional R&D service team of 800 people, including more than 250 doctors/masters.

Since its establishment 19 years ago, the company has focused on technology research and development in the pharmaceutical industry, achieving remarkable results in pharmaceutical technology research. To date, it has successfully developed over 350 new drug technologies and obtained more than 300 production and clinical approvals for domestic registration. Huawei Pharmaceuticals' customer base includes many domestic and foreign enterprise groups, innovative enterprises, and listed companies such as Yangtze River Pharmaceutical Group, Harbin Pharmaceutical Group, Zhengda Tianqing, China National Pharmaceutical Group, Taiji Group, Fosun Pharmaceutical, Kangyuan Pharmaceutical, Qilu Pharmaceutical, Lunan Pharmaceutical, Huayuan Group, Guangzhou Pharmaceutical Group, Luoxin Pharmaceutical, Kelun Pharmaceutical, Ruiyang Pharmaceutical, Kangenbei, Hengrui Pharmaceutical, Xiansheng Pharmaceutical, Beida Pharmaceutical, BeiGene, Innovent, Quintiles, Novartis, Roche, Bayer, etc. More than 50 Chinese pharmaceutical industry enterprises are customers of Huawei Pharmaceutical Services.

Huawei Pharmaceuticals completed asset restructuring with A-share listed company Xinjiang Baihuacun Co., Ltd. (600721) in 2016, and is currently a listed company in the Chinese capital market with drug research and development as its main business. Can provide partners with drug discovery CMC、 Comprehensive services and integrated solutions for the entire process of new drug development, including clinical CRO, drug registration, CMO/API supply.